Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Becton Dickinson ( (BDX) ) is now available.
Becton, Dickinson and Company is a global medical technology firm focused on developing, manufacturing and selling medical devices, instrument systems and reagents. Through subsidiaries such as Becton Dickinson Euro Finance S.à r.l., the company taps European capital markets to support its financing needs and to manage its debt profile across multiple jurisdictions.
Becton Dickinson Euro Finance S.à r.l. issued €600 million of 3.855% notes due 2033 on May 20, 2026, in an underwritten public offering fully and unconditionally guaranteed on a senior unsecured basis by BD. The notes include flexible optional redemption terms, change-of-control repurchase provisions, tax gross-up protections and standard covenants, and BD plans to use the proceeds, alongside cash on hand, to refinance its 1.208% notes due June 4, 2026, and for general corporate purposes.
The most recent analyst rating on (BDX) stock is a Buy with a $204.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.
Spark’s Take on BDX Stock
According to Spark, TipRanks’ AI Analyst, BDX is a Neutral.
The score is driven by solid financial quality—especially strong free cash flow and improving leverage—plus supportive earnings-call guidance with raised adjusted EPS. These positives are tempered by weak technicals (price below key moving averages with negative MACD) and a less helpful valuation signal due to a negative P/E, alongside near-term operational headwinds (tariffs, China, and a temporary FDA-related shipment hold).
To see Spark’s full report on BDX stock, click here.
More about Becton Dickinson
Becton, Dickinson and Company is a global medical technology firm focused on developing, manufacturing and selling medical devices, instrument systems and reagents. Through subsidiaries such as Becton Dickinson Euro Finance S.à r.l., the company taps European capital markets to support its financing needs and to manage its debt profile across multiple jurisdictions.
Becton Dickinson Euro Finance S.à r.l. issued €600 million of 3.855% notes due 2033 on May 20, 2026, in an underwritten public offering fully and unconditionally guaranteed on a senior unsecured basis by BD. The notes include flexible optional redemption terms, change-of-control repurchase provisions, tax gross-up protections and standard covenants, and BD plans to use the proceeds, alongside cash on hand, to refinance its 1.208% notes due June 4, 2026, and for general corporate purposes.
Average Trading Volume: 2,900,462
Technical Sentiment Signal: Strong Sell
Current Market Cap: $39.22B
For an in-depth examination of BDX stock, go to TipRanks’ Overview page.